Several clinical trials assessing the use of immune checkpoint inhibitors in glioblastoma are ongoing, whilst the combination of TTFields with anti-PD-1 therapy is currently being assessed in patients with NSCLC (NCT02973789),91 potentially providing an important platform for future clinical studies assessing a similar combination to treat patients with a glioblastoma. This evidence concerns the gene PDCD1 and glioblastoma.